Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

M C Genovese,R Aranda,N Schmidely,M Schiff,T Li,M Dougados,J-C Becker,J Teng,M Le Bars,M Luggen

doi:10.1136/ard.2007.074773

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

M C Genovese, R Aranda + Show 8 more

https://doi.org/10.1136/ard.2007.074773

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Oct 5, 2007
Citations: 258

Affiliation: Bristol-Myers Squibb (United States), Bristol-Myers Squibb (France), Denver Arthritis Clinic, Stanford University, Hôpital Cochin, University of Cincinnati, University of Cincinnati Medical Center

#Efficacy Of Abatacept #American College Of Rheumatology + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Objective:To evaluate the safety and efficacy of abatacept during 2 years of the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate responders) trial in patients with rheumatoid arthritis.Methods:Patients completing the...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.